论文部分内容阅读
目的观察孟鲁司特联合舒利迭治疗重度哮喘的临床疗效。方法选择我院自2011年1月至2012年6月收治的75例重度哮喘患者的临床资料,根据随机的原则,将患者分为观察组38例与对照组37例,给予对照组患者单纯使用舒利迭,观察组患者孟鲁司特联合应用舒利迭,连续给予患者使用12周药量,观察患者的临床疗效。结果患者经治疗后临床症状得到不同程度改善,但观察组患者得分情况明显优于对照组,两组患者对比,结果具有显著性差异(P<0.05)。结论在单纯应用舒利迭效果不佳的情况下,配合应用孟鲁司特是治疗重度哮喘的新选择。
Objective To observe the clinical efficacy of montelukast combined with seretide in the treatment of severe asthma. Methods The clinical data of 75 patients with severe asthma admitted in our hospital from January 2011 to June 2012 were selected. According to the randomized principle, the patients were divided into observation group (38 cases) and control group (37 cases), and patients in the control group Seretide, montelukast observation group patients combined with seretide, continuous administration of patients with 12-week dose to observe the clinical efficacy of the patients. Results The clinical symptoms of the patients improved to some extent after treatment. However, the score of the observation group was significantly better than that of the control group. There was significant difference between the two groups (P <0.05). Conclusion In the case of poor effect of the simple application of seretide, montelukast in combination with the treatment of severe asthma is a new choice.